Aldeyra (NASDAQ:ALDX) is a biotechnology company focused primarily on the development of products to treat immunological and orphan diseases that are related to free aldehydes, a toxic chemical species implicated in inflammation and other pathology.

Boston Oncology seeks to increase access to specialty medications in developing nations through the acquisition of product licenses and manufacturing processes as part of a world-class portfolio of small-molecule and biotechnology therapies.

Supporting early stage medical device, biotechnology and pharmaceutical companies in strategic planning, fundraising and operations.

An early stage medical device company focused on imaging and telepathology to detect melanoma, basal and squamous skin cancers and inflammatory skin disease.• Organized the strategy to recapitalize the company through an IPO in December 2011, eliminating convertible debt overhang and related penalties, preventing the bankruptcy of the company.• Reworked the company’s strategic plan, outlining value-creating milestones and multiple revenue streams to enhance shareholder value.

World market leader in proprietary bioengineered polymer microsphere platform technologies used therapeutically in women’s health and in the delivery of chemotherapeutic compounds. • Working directly with the Board of Directors, prepared and executed plan to sell the company, including leadership of the due diligence team, and negotiation of the definitive merger agreement. • Closed preferred equity round providing needed liquidity to restart the company and prevent delisting from the NASDAQ exchange. Raised, negotiated and closed follow on common stock financing. • Developed and implemented comprehensive investor relations campaign, growing BioSphere’s market capitalization 244% in approximately 14 months. Established research analyst, sell-side coverage with five investment banks. Upgraded shareholder base to tier-1 life science investors. • Settled litigation related to product distribution and product liability claims against BioSphere that threatened the company’s economic viability, with the resolution of the last lawsuit clearing the way for the sale of the company.• Negotiated clinical research and distribution agreement with Nippon Kayaku Pharmaceuticals in Japan for planned market access of BioSphere’s drug delivery platform for the treatment of liver cancer. Negotiated and closed joint product collaboration and manufacturing agreement with DuPont. • Recruited accounting team to establish financial controls for global implementation of Sarbanes-Oxley.

Biopharmaceutical executive services to early-stage companies and venture investors.• Cofounded pharmaceutical company focused on therapeutic targets in hepatocellular carcinoma. • Developed business strategy and company positioning for multiple clients.

North American operations of Ares-Serono, a Swiss multinational biopharmaceutical corporation.• Responsible for Serono’s North American accounting, treasury, tax, business analysis and information technology organizations with annual revenue of $500 million. • Segmented combined entity into strategic business units for Reproductive Health, Metabolic Therapy, Pediatric Endocrinology and Neurology, sharpening focus and increasing shareholder return.• Implemented Balanced Scorecard of key performance indicators, including financial metrics, customer market focus, internal performance and organizational effectiveness. Introduced supply-chain management in North America, including an 18-month rolling sales forecast, increasing accuracy to 95%. • Settled IRS audit related to international transfer pricing, manufacturing, research and development and interest deductions. Initial proposed income adjustment by IRS of $100 million, with a final settlement of $5 million. • Managed numerous restructurings, reducing overhead by over $30 million. • Negotiated $50 million corporate headquarters expansion plan, including $26 million in financing.

Created the company’s first integrated managed health care strategy. Negotiated contracts with leading prescription benefit companies and health maintenance organizations.

Developed integrated business strategy in Puerto Rico for a sterile filling and lyophilization facility for 20 million doses. Negotiated with big-pharma partners and closed a joint venture with DuPont Merck valued at $120 million.

Project manager for the construction of a 41,000-square-foot, $40 million recombinant growth hormone c-GMP manufacturing plant on critical path for product registration.

Managed financial reporting, planning and analysis for Serono’s pharmaceutical and biotechnology operations.